



Contact: Julie Bryant
VP Business Development and Marketing
GeneGo, Inc.
(858) 756 7996
julie@genego.com

ORGANON EXTENDS METACORE LICENSE AND ADDS METALINK

St. Joseph, MI. October 2nd, 2007 – GeneGo, Inc., the leading systems biology tools company, announced today that Organon, the human health care business unit of Akzo Nobel, have extended their GeneGo software and database licenses. In addition to extending their MetaCore license, Organon has also added MetaLink so that they can upload their own interaction data and visualize it in the context of MetaCore’s manually curated content.

GeneGo offers easy to use automated workflows that casual users can use and these are now also available through their new product 1-2-3 workflow which is a “pay as you go” business model. GeneGo also covers human, mouse, rat, dog, worm, chicken, fly, chimpanzee and yeast which is very important for our customers.

“GeneGo has demonstrated the capability to develop a good pharma oriented bioinformatics tool in the past years” said Peter Groenen, project manager for pharmacogenetics at Organon. “We have now started to use their software for more advanced projects to support our translational medicine efforts.”

“Organon has been a good, loyal GeneGo customer for years and we are pleased they have extended their license,” said Julie Bryant, GeneGo’s VP of Business Development. “We have received good development feedback from Organon over the years and implemented their ideas in MetaCore”.

About GeneGo

GeneGo develops systems biology technology for life science research. The original computational MetaDiscovery™ platform allows an integration and expert analysis of different kinds of experimental data (mRNA expression, proteomics, metabolomics, microRNA assays and other phenotypic data) and relevant bioactive chemistry (metabolites, drugs, other xenobiotics) within the framework of curated biological pathways and networks. GeneGo’s flagship product, MetaCore 5.0™, assists pharmaceutical scientists in the areas of target selection and validation, identification of biomarkers for disease states and toxicology. The second product, MetaDrug2.0™ is designed for prediction of human metabolism, toxicity

and biological effects for novel small molecules compounds. MetaBase™ represents the knowledge base for MetaCore. For more information, please visit the company's web site at www.genego.com

MetaCore™, MetaBase™, MetaDrug™, MetaLink™, MetaDiscovery™, MetaTox™ and MetaMiner™, 1-2-3 Workflow™ are trademarks of GeneGo, Inc.